Core Insights - Amicus Therapeutics reported total revenue of $528.3 million for the year 2024, marking a 33% increase year-over-year [1][4][3] - The company projects revenue growth for 2025 to be between 17% and 24% at constant exchange rates (CER) [1][4][7] - Amicus anticipates achieving positive GAAP net income during the second half of 2025 [1][7][12] Financial Performance - Total revenues for 2024 were $528.3 million, with a fourth-quarter revenue of $149.7 million, reflecting a 30% increase year-over-year [4][5] - Galafold® net product sales for 2024 were $458.1 million, an 18% increase year-over-year, while Pombiliti® + Opfolda® sales reached $70.2 million, a significant increase of 507% [5][6][12] - The company reported a GAAP net loss of $56.1 million for 2024, an improvement from a loss of $151.6 million in 2023 [12][24] Product Insights - Galafold is indicated for treating Fabry disease and is approved in over 40 countries, with approximately 2,730 patients using the drug by the end of 2024 [12][13] - Pombiliti + Opfolda received regulatory approval in multiple countries, including Australia, and is expected to see first commercial patients treated in early 2025 [5][12][16] Future Guidance - For 2025, Amicus expects Galafold revenue growth of 10% to 15% and Pombiliti + Opfolda growth of 65% to 85% at CER [7][12] - The company aims to surpass $1 billion in total sales by 2028, driven by its current product portfolio [6][12] Operational Highlights - Total GAAP operating expenses for 2024 were $450.5 million, a slight increase from $439.2 million in 2023 [12][24] - Cash, cash equivalents, and marketable securities totaled $249.9 million at the end of 2024, showing stability compared to previous quarters [12][24]

2024 Total Revenue of $528.3M, a 33% Increase Year-over-Year Projecting 2025 Total Revenue Growth of 17-24% at CER Anticipate Achieving Positive GAAP Net Income During H2 2025 Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced financial results for the full-year ended December 31, 2 ...

NEW YORK, Feb. 17, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Amicus Therapeutics, Inc. (NASDAQ:FOLD) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms. If you are a long-term FOLD stockholder please contact Justin Kuehn, Esq. here, by email at justin@kuehn.law, or call (833) 672-0814.  The cons ...

Wall Street analysts forecast that Amicus Therapeutics (FOLD) will report quarterly earnings of $0.10 per share in its upcoming release, pointing to a year-over-year increase of 190.9%. It is anticipated that revenues will amount to $149.53 million, exhibiting an increase of 29.9% compared to the year-ago quarter.The current level reflects a downward revision of 80% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively re ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Amicus Therapeutics (FOLD) reports results for the quarter ended December 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on February 19, 2025, might help the stock move higher if these key numbers are bet ...

PRINCETON, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, February 19, 2025, at 8:30 a.m. ET to discuss financial results for the full-year ended December 31, 2024. Participants and investors interested in accessing the call by phone will need to register using the online registration form. After registering, all phone participants will receive a dial-in number along with a personal ...

PRINCETON, N.J., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that two oral presentations and 20 posters across its development programs will be included at the 21st Annual WORLDSymposium™ 2025, being held February 3-7, 2025 in San Diego, CA. “As part of our ongoing efforts to advance our scientific leadership in Fabry and Pompe diseases, Amicus researchers will present two oral presentations and 20 posters at this year’s WORLDSymposium,” said Bradley Campbell, Presi ...

Washington, D.C., Jan. 23, 2025 (GLOBE NEWSWIRE) -- The New Civil Liberties Alliance has filed an amicus curiae brief in Burgess v. Whang, urging the U.S. Court of Appeals for the Fifth Circuit to uphold a preliminary injunction stopping the Federal Deposit Insurance Corporation’s (FDIC) unconstitutional administrative enforcement proceeding against Cornelius Campbell Burgess. FDIC is trying to heavily fine Mr. Burgess, a former executive for a small Texas bank, and ban him from the banking industry for lif ...

Amicus Therapeutics (FOLD) announced preliminary total revenues for the fourth quarter and full-year 2024. The company’s top line currently comprises sales of the lead product, Galafold (migalastat), which is approved for treating Fabry disease and Pombiliti + Opfolda.The FDA approved Pombiliti + Opfolda, a two-component therapy for treating late-onset Pompe disease, in September 2023.Along with the preliminary results, Amicus also outlined key strategic priorities and outlook for 2025.In the past year, sha ...

Company Overview - Amicus Therapeutics is a global biotechnology company focused on developing and commercializing novel medicines for rare diseases [1] - The company is dedicated to advancing a pipeline of first- or best-in-class medicines for rare diseases [1] - Amicus Therapeutics is committed to delivering high-quality medicines for patients with rare diseases [1] Financial Performance - Total revenue in 2024 reached $528.5 million, representing a year-over-year increase of 32% [7] - Fourth quarter total revenue was $149.9 million [7] - The company anticipates total revenue growth of 17-24% on a constant currency basis for 2025 [7] - Galafold net product sales in 2024 were $458.2 million, a year-over-year increase of 18% [7] - Pombiliti + Opfolda net product sales in 2024 were $70.3 million [7] - The company anticipates achieving positive GAAP Net Income during H2 2025 [7] Product Highlights - Galafold is an oral pharmacological chaperone for the treatment of Fabry disease in adults with amenable GLA variants [14] - Pombiliti + Opfolda is a two-component therapy for the treatment of late-onset Pompe disease [17] - As of the end of 2024, there were ~2,730 patients living with Fabry disease on Galafold [7] - There were ~220 patients treated or scheduled with Pombiliti + Opfolda as of the end of 2024 [7] Strategic Priorities - The company is focused on delivering significant long-term revenue growth and anticipates surpassing $1 billion in total sales by 2028 [7] - Amicus is advancing ongoing studies to broaden labels and scientific leadership in Fabry and Pompe diseases [7] - The company reached a settlement with Teva on the Galafold U.S. patent litigation, preventing Teva from commercializing generic migalastat in the U.S. until Jan 2037 [7] Market Expansion - Multiple Pombiliti + Opfolda pricing and reimbursement agreements were achieved in Italy, Sweden, Switzerland, and Czech Republic [7] - The company anticipates new regulatory decisions in Australia, Canada, and Japan in 2025 [7] - Additional reimbursement agreements are expected throughout 2025 [7] Corporate Updates - Bradley Campbell, President and CEO, highlighted the company's significant revenue growth and non-GAAP profitability in 2024 [5] - The company's strong intellectual property position and global rare disease organization are expected to enable sustainable revenue growth [5] - Mr. Campbell will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025 [21]